Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational Medicine
Vaxart, Inc. (VXRT)
Last vaxart, inc. earnings: 3/19 04:01 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
Challenge Study measured safety, efficacy against infection and symptomatic disease as well as viral shedding Machine learning analyses identified statistically significant correlates of protection and will be incorporated into the development of Vaxart’s second-generation norovirus vaccine candidate, which is being evaluated in a Phase 1 clinical trial SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the publication of complete data from a Phase 2b challenge study of its first-generation oral pill norovirus vaccine candidate (NCT05212168) in Science Translational Medicine. Consistent with preliminary data reported in September 2023, the complete results show that the trial met five of its six primary endpoints and demonstrate the safety, efficacy, and immunogenicity of the vaccine candidate. Additional data included in the current publication include results from machine learning analyses that identify functional blocking
Show less
Read more
Impact Snapshot
Event Time:
VXRT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VXRT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VXRT alerts
High impacting Vaxart, Inc. news events
Weekly update
A roundup of the hottest topics
VXRT
News
- Vaxart, Inc. (VXRT) Shareholder/Analyst Call Transcript [Seeking Alpha]Seeking Alpha
- Vaxart, Inc. (VXRT) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Vaxart Q3 2025 Earnings Preview [Seeking Alpha]Seeking Alpha
- Vaxart to Host Upcoming Conference CallsGlobeNewswire
- Vaxart to Present Research on Second-Generation Norovirus Oral Pill Vaccine Candidate at IDWeek 2025GlobeNewswire
VXRT
Earnings
- 11/13/25 - Beat
VXRT
Sec Filings
- 12/8/25 - Form 4
- 12/8/25 - Form 144
- 12/5/25 - Form 4
- VXRT's page on the SEC website